Circulating tumor markers in breast cancer: Accepted utilities and novel prospects

Breast Cancer Research and Treatment

Volumn 52, Issue 1-3, 1998, Pages 239-259

  Stearns, Vered ^a   Yamauchi, Hideko ^a   Hayes, Daniel F ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Metastatic disease; Serum markers; Tumor markers; Tumor associated antigens

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROTEIN P53; TUMOR MARKER;

ANGIOGENESIS; ANTIBODY RESPONSE; BLOOD LEVEL; BREAST CANCER; CANCER DIAGNOSIS; CELL ADHESION; CELL INVASION; DIAGNOSTIC VALUE; HUMAN; METASTASIS; ONCOGENE NEU; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032431294     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006137619153     Document Type: Review

References (112)

1. Hayes DF, Bast R, Desch CE, Fritsche H, Kemeny NE, Jessup J, Locker GY, Macdonald J, Mennel RG, Norton L, Ravdin P, Taube S, Winn R: A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466, 1996
2. Sell S: Cancer markers of the 1990s: An introduction. In: Sell S (ed) Serological Cancer Markers. Humana Press, Totowa NJ, 1992, pp 1-17
3. Morelli D, Lazzerini D, Cazzaniga S, Squicciarini P, Bignami P, Maier JAM, Sfondrini L, Menard S, Colnaghi MI, Balsari A: Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancer. Clin Cancer Res 7:1221-1225, 1998
4. Folkman J: Tumor angiogenesis. In: Holland JF (ed) Cancer Medicine. Lea & Febiger, Melbourne PA, 1991, pp
5. Takei Y, Kurbone M, Uchida A, Hayashi K: Serum concentrations of basic fibroblast growth factor in breast cancer. Clin Chem 40:1980-1981, 1994
6. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, Tominaga T: Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2:821-826, 1996
7. Janeway CAJ, Travers P: The induction, measurement, and manipulation of the immune response. In: (eds) Immunobiology: The immune system in health and disease. Garland Publishing Inc, New York, 1997, pp 2:1-2:52
8. Hayes DF: Tumor markers for breast cancer: Current utilities and future prospects. In: Hayes DF (ed) Hematology/Oncology Clinics of North America: Tumor Markers in Adult Solid Malignancies. W.B. Saunders Co., Philadelphia, 1994, pp 485-506
9. ASCO Expert Panel: 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 16:793-795, 1998
10. ASCO Expert Panel: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: Report of the American Society of Clinical Oncology expert panel. J Clin Oncol 14:2843-2877, 1996
11. Hayes DF, Trock B, Harris AL: Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? Breast Cancer Res Treat 52:305-319, 1998 (this issue)
12. Schwartz MK: Circulating and tissue markers in the longitudinal management of breast cancer patients. Adv Exp Med Biol 353:47-53, 1994
13. Graves R, Hilgers J, Fritche H, Hayes DF, Robertson JFR: MUC-1 mucin assays for monitoring therapy in metastatic breast cancer. in press
14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
15. Hayes DF, Cirrincione C, Carney W, Rodrigue S, Berry D, Younger J, Panasci L, Millard F, Duggan D, Henderson IC, Kufe DW: Elevated circulating HER-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 12:58a, 1993
16. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S, Lipton A: Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10:1436-1443, 1992
17. Hayes DF: Angiogenesis and breast cancer. In: Shapiro CL, Henderson IC (eds) Hematology/Oncology Clinics of North America. W.B. Saunders Co., Philadelphia, 1994, pp 51-71
18. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini N, Gaudino G, Tamagone L, Coffer A, Comoglio PM: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629-641, 1992
19. Smith MEF, Thomas JA: Cellular expression of lymphocyte function associated antigens and the inter-cellular adhesion molecule-1 in normal tissue. J Clin Pathol 43:893-900, 1990
20. Kotch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ: Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376:517-519, 1995
21. Westley BR, May FEB: Cathepsin D and breast cancer. Eur J Cancer 32A:15-24, 1995
22. Ossowsky L, Clunie G, Masucci MT, Blasi F: In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 115:1107-1112, 1991
23. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, Dybkjaer E, Dano K, Brunner N: ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868-1876, 1997
24. Meijer WG, van der Veer E, Willemse PH: Biochemical parameters of bone metabolism in bone metastases of solid tumors. Oncol Rep 5:5-21, 1998
25. Hayes DF: Serum tumor markers for breast cancer. In: Senn HJ (eds) Proceedings, 5th Annual Conference, Adjuvant Therapy in Primary Breast Cancer. Recent Results of Cancer Research. Springer-Verlag, Heidelberg, 1996, pp 101-113
26. Luthgens ML, Oher P: Clinical cancer markers: Diagnosis, prognosis, and monitoring. In: Sell S (ed) Serological Cancer Markers. Humana Press, Totowa NJ, 1992, pp 19-29
27. Smith TM, Lee MK, Szabo CI, Jerome N, McEuen M, Taylor M, Hood L, King MC: Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res 6:1029-1049, 1996
28. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, et al: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12:333-337, 1996
29. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396, 1998
30. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ: Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47:111-120, 1998
31. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D: Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90:911-915, 1998
32. Eddy DM: Screening for breast cancer. Ann Int Med 111:389-399, 1989
33. Kerlikowske K: Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr 22:79-86, 1997
34. Hare WS, Tjandra JJ, Russell IS, Collins JP, McKenzie IF: Comparison of mammary serum antigen assay with mammography in patients with breast cancer. Med J Aust 149:402-406, 1988
35. Ward BG, Joy GJ, Ramm LE, Baker CA, McGuckin MA: Comparative study of mammography and mammary serum antigen estimation for breast cancer screening. Med J Aust 157:161-164, 1992
36. Tondini C, Hayes DF, Kufe D: Circulating tumor markers in breast cancer. In: Henderson IC (ed) Diagnosis and Therapy of Breast Cancer. W.B. Saunders Co., Philadelphia, 1989, pp 653-674
37. Devine PL, Duroux MA, Quin RJ, McGuckin MA, Joy GJ, Ward BG, Pollard CW: CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer. Breast Cancer Res Treat 34:245-251, 1995
38. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363-3367, 1997
39. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T: Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345:621-622, 1995
40. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52:6380-6384, 1992
41. Vojtesek B, Kovarik J, Dolezalova H, Nenutil R, Havlis P, Brentani RR, Lane DP: Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br J Cancer 71:1253-1256, 1995
42. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ: The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 69:1115-1119, 1994
43. Willsher PC, Pinder SE, Robertson L, Nicholson RI, Ellis IO, Bell JA, Blamey RW, Green JA, Robertson JF: The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 16:927-930, 1996
44. Gold P, Freedman S: Demonstration of tumor-specific antigens in human colonic carcinomata by immunologic tolerance and absorption techniques. J Exp Med 121:439-462, 1965
45. Chevinsky AH: CEA in tumors of other than colorectal origin. Semin Surg Oncol 7:162-166, 1991
46. Mazoujian G, Pinkus GS, Davis S, Haagensen DE Jr: Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast: a marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 110:105-112, 1983
47. Cardoso de Almeida PC, Pestana CB: Immunohistochemical markers in the identification of metastatic breast cancer. Breast Cancer Res Treat 21:201-210, 1992
48. Haagensen D, Mazoujian G, Holder W, Kister S, Wells S: Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients. Ann Surg 185:279-285, 1977
49. Yu H, Levesque MA, Clark GM, Diamandis EP: Prognostic value of prostate-specific antigen for women with breast cancer: A large United States cohort study. Clin Cancer Res 4:1489-1497, 1998
50. Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque MA, Diamandis EP: Prostate-specific antigen in serum of women with breast cancer. Br J Cancer 72:728-731, 1995
51. Isola J, Holli K, Oksa H, Teramoto Y, Kallioniemi O-P: Elevated erbB2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 73:652-658, 1994
52. Andersen TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL: Detection of c-erbB-2 related protein in sera from breast cancer patients: Relationship to ERBB2 gene amplification and c-erbB-2 protein over-expression in tumour. Acta Oncologica 34:499-504, 1995
53. Meden H, Marx D, Schauer A, Wuttke W, Kuhn W: Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer. Anticancer Res 17:757-760, 1997
54. Sheen-Chen SM, Eng HL, Sheen CW, Cheng YF, Chou FF, Chen WJ: Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer. Anticancer Res 17:2823-2826, 1997
55. Matsuura N, Narita T, Mitsuoka C, Kimura N, Kannagi R, Imai T, Funahashi H, Takagi H: Increased concentration of soluble E-selectin in the sera of breast cancer patients. Anticancer Res 17:1367-1372, 1997
56. Brouillet JP, Dufour F, Lemamy G, Garcia M, Schlup N, Grenier J, Mani JC, Rochefort H: Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay. Cancer 79:2132-2136, 1997.
57. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326:1756-1761, 1992
58. Robert J, Hoerni B: Age dependence of the early phase pharmacokinetics of doxorubicin. Cancer Res 43:4467-4469, 1983
59. Ciatto S, Pacini P, Azzini V, Neri A, Jannini A, Gosso P, Molino A, Capelli MC, di Costanzo F, Pucciatti MA, et al: Preoperative staging of primary breast cancer. A multicentric study. Cancer 61:1038-1040, 1988
60. Hayes DF, Zurawski VR Jr, Kufe DW: Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4:1542-1550, 1986
61. Hayes DF, Henderson IC, Shapiro CL: Treatment of metastatic breast cancer: Present and future prospects. Semin Oncol 22:5-21, 1995
62. Colomer R, Ruibal A, Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64:1674-1681, 1989
63. Bremer K, Eklund G, Bjorklund B: Notable relationship between the level of tumor marker TPS in serum and survival in breast cancer. Anticancer Res 16:905-909, 1996
64. Sledge G, Neuberg D, Ingle J, Martino S, Wood W: Phase III trial of doxorubicin vs. paclitaxel vs doxorubicin + paclitaxel as first line therapy for metastatic breast cancer: An Intergroup trial. Proc Am Soc Clin Oncol 16:1a, 1997
65. Colomer R, Aparicio J, Montero S, Guzman C, Larrodera L, Cortes-Funes H: Low levels of basic fibro-blast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 76:1215-1220, 1997
66. Sliutz G, Tempfer C, Obermair A, Dadak C, Kainz C: Serum evaluation of basic FGF in breast cancer patients. Anticancer Res 15:2675-2677, 1995
67. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T: Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1:1031-1034, 1995
68. Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, Iwanari H, Tominaga T: Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res 4:659-664, 1998
69. Maemura M, Iino Y, Yokoe T, Horiguchi J, Takei H, Koibuchi Y, Horii Y, Takeyoshi I, Ohwada S, Morishita Y: Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer. Cancer Lett 126:215-220, 1998
70. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Janicke F, Klijn JG: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101-6105, 1992
71. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61:597-600, 1995
72. Hebbar M, Revillion F, Louchez MM, Vilain MO, Fournier C, Bonneterre J, Peyrat JP: The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer. Clin Cancer Res 4:373-380, 1998
73. Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa AP, Chiba I, Takahashi T, Nau MM, Callahan R, et al: Mutations in the p53 gene in primary human breast cancers. Cancer Res 51:6194-6198, 1991
74. Lowe SW, Bodis S, McClatchey A: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
75. Kandioler-Eckersberger D, Taucher B, Steiner M, Udas M, Mannhalter C, Steger G, Jakesz R: P53 genotype and major response to anthracycline or paclitaxel based neoadjuvant treatment in breast cancer patients. Proc Am Soc Clin Oncol 17:102a (abstr 392), 1998
76. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991
77. Hayes DF: Should we treat HER, too? J Clin Oncol 14:697-699, 1996
78. Gaasparini G, Harris A: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13:7652-7682, 1995
79. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992
80. Muss HB, Thor A, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and S-phase activity predict response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Mod 330:1260-1266, 1994
81. Colomer R, Montere S, Lluch A, Ojeda B, Barnadas A, Martin M, Massuti B, Cortes-Funes H, Vega F, Bonito M: Circulating HER-2/neu predicts resistance to Taxol/Adriamycin in metastatic breast carcinoma: Preliminary results of a multicentric study. Proc Am Soc Clin Oncol 16:140a, 1997
82. Stender MJ, Neuberg D, Wood W, Sledge G: Correlation of circulating c-erb B-2 extracellular domain (Her-2) with clinical outcome in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 16:154a (abstr 541), 1997
83. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995
84. Yamauchi H, O'Neill A, Gelman R, Carney W, Hosch S, Hayes DF: Prediction of response to anti-estrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15:2518-2525, 1997
85. Fehm T, Maimonis P, Katalinic A, Jager WH: The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 55:33-38, 1998
86. Harris LN, Trock B, Berris M, Esteva-Lorenzo F, Paik S: The role of ERBB2 extracellular domain in predicting response to chemotherapy in breast cancer patients. Proc Am Soc Clin Oncol 15:108a, 1996
87. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jager W: Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 43:87-95, 1997
88. Baselga J, Seidman AD, Rosen PP, Norton L: HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications. Oncology 11:43-48, 1997
89. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz C, Dantis L, Sklarin N, Seidman A, Hudis C, Moore J, Rosen P, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
90. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Paton V, Shak S, Lieberman G, Slamon D: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 17:97a(abstr 376), 1998
91. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton L: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a (abstr 377), 1998
92. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
93. Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG: Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87:751-756, 1995
94. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998
95. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
96. GIVIO Investigators: Impact of follow-up and testing on survival and health-related quality of life in breast cancer patients: A multicenter randomized controlled trial. J Am Med Assoc 271:1587-1593, 1994
97. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V: Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial. J Am Meal Assoc 271:1593-1597, 1994
98. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Gimenez N, Pahisa J, Velasco M, et al: Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36:41-48, 1995
99. Molina R, Jo J, Zanon G, Filella X, Farrus B, Munoz M, Latre M, Pahisa J, Valasco M, Fernandez P, Estape J, Ballesta A: Utility of c-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer 74:1126-1131, 1996
100. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S: Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol 35:80-83, 1994
101. Hayes DF, Zurawski V, Kufe DW: Comparison of circulating breast cancer associated antigen CA15-3 with CEA in patients with breast cancer. Proc Am Soc Clin Oncol 5:12a, 1986
102. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW: Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48:4107-4112, 1988
103. Willsher PC, Beaver J, Blamey RW, Robertson JF: Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: Comparison with CA 15.3 and CEA. Anticancer Res 15:1609-1611, 1995
104. Schuurman JJ, Bong SB, Einarsson R: Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res 16:2169-2172, 1996
105. Soletormos G, Nielsen D, Schioler V, Skovsgaard T, Dombernowsky P: Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem 42:564-575, 1996
106. Hayes DF, Kiang DT, Korzun A, Tondini C, Wood W, Kufe D: CA15-3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 7:38a, 1988
107. Eisen T, Boshoff C, Vaughan MM, Pyle L, Smith IE, Johnston SRD, Bunker C, Kitchen P, Rowe A, Gore ME: Anti-angiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancer with thalidomide: A phase II study. Proc Am Soc Clin Oncol 17:441a(abstr 1699), 1998
108. Chan D, Beveridge R, Muss H, Fritsche H, Hortobagyi G, Theriault R, Kiang D, Kennedy BJ, Evelegh M: Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15:2322-2328, 1997
109. Pavesi F, Lotzniker M, Scarabelli M, Mauro E, Visconti G, Nicolato E, Moratti R: Circulating CA 549 and other associated antigens in breast cancer patients. Oncology 51:18-21, 1994
110. Donadeo A, Micelli G, Quaranta M, Atlante A, Schittulli F: MCA performance in preoperative breast cancer patients. Anticancer Res 15:527-529, 1995
111. Willsher PC, Beaver J, Pinder S, Bell JA, Ellis IO, Blarney RW, Robertson IF: Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 40:251-255, 1996
112. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, Martin M, Van Oosterom AT: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76:238-243, 1997